We are live on ! Find out more
IMMU

Immunomedics Inc
IMMU

Delisted

IMMU was delisted on the 22nd of October, 2020.

109 hedge funds and large institutions have $221M invested in Immunomedics Inc in 2016 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 46 increasing their positions, 18 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

221% more call options, than puts

Call options by funds: $13.4M | Put options by funds: $4.17M

156% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 18

67% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 12

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

32% more capital invested

Capital invested by funds: $168M → $221M (+$53.1M)

8% more funds holding

Funds holding: 101109 (+8)

Holders
109
Holders Change
+8
Holders Change %
+7.92%
% of All Funds
2.72%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
20
Increased
46
Reduced
18
Closed
12
Calls
$13.4M
Puts
$4.17M
Net Calls
+$9.22M
Net Calls Change
+$5.88M

IMMU Hedge Fund Activity: Q4 2016 in Review

109 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q4 2016, worth a combined $221M — up 32% from $168M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new IMMU positions and 12 closed out — a net gain of 8 holders — while 46 added to existing stakes and 18 trimmed.

The largest buyer was EverPoint Asset Management, opening a new position worth an estimated $9.87M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $5.1M sold.

  • 109 institutional investors held Immunomedics Inc (IMMU) as of Q4 2016, up from 101 in Q3 2016.
  • Funds reported $221M of Immunomedics Inc stock for Q4 2016, up 32% quarter-over-quarter.
  • 20 funds opened new Immunomedics Inc positions in Q4 2016 and 12 closed out, a net change of +8 holders.
  • The largest Immunomedics Inc buyer in Q4 2016 was EverPoint Asset Management, an estimated $9.87M added.
  • The largest Immunomedics Inc seller in Q4 2016 was Balyasny Asset Management, an estimated $5.1M sold.

Based on aggregated 13F filings for Q4 2016.